SlideShare a Scribd company logo
1 of 2
Download to read offline
Hospital-Acquired Pneumonia/
Ventilator-Associated Pneumonia
(HAP/VAP) Case Study
IMPROVING STUDY START UP AND
RECRUITMENT FOR A DRUG-DEVICE
CLINICAL TRIAL
Ventilated patients in a hospital setting are at risk of developing pneumonia, which is often
treated with an IV-delivered antibiotic. In collaboration with an agile biotech company, a large
pharmaceutical company was running a program to investigate the clinical efficacy and safety of
a drug-device combination for intubated, mechanically ventilated patients by delivering a localized,
lower dosage of an antibiotic within the lungs as compared to systemically-administered antibiotics.
Due to the sponsor’s shifting alliance agreements, Covance was selected to assume its in-progress,
Phase III clinical trial. This case study explores the challenges faced in study start up, recruitment and
data management.
The Challenges: Recruiting a global population in a complex
infectious disease study
ICU studies are inherently difficult due to the complexities of
patients’ conditions while in the hospital, the need to obtain
consent for temporarily incapacitated patients and the massive
amount of associated data that is generated in the medical records.
When Covance received this study, there had already been three
amendments to the protocol and the trial was behind schedule
for startup and recruitment. With over 250 sites encompassing
25 different countries and their respective regulatory
requirements involved, Covance needed to quickly make major
progress to get the study back on track.
Initial enrollment criteria were very strict, allowing only a 24-hour window to complete patient screening and start
the study regimen. While standard of care assessments were allowed, it was still challenging to enroll patients.
The final challenge involved managing the data cleaning process with the sponsor to support the Data
Monitoring Committee (DMC), as many data points were collected and had to be correctly mapped within the
Electronic Data Capture (EDC) system.
Key Actions
▶ Developed hands-on solutions to
address lagging recruitment
▶ Worked directly with sites to
understand the barriers to
recruitment and share success
stories among investigators
▶ Built a robust communications
effort to meet the recruitment goals,
achieve database lock and submit the
clinical study report (CSR) on time
The Actions: Setting up sites for success
Covance first worked with the sponsor to amend the protocol and allow for a 48-hour window instead
of the initial restrictive 24-hour window to increase the potential for successful enrollment. With the
goal of recruiting 725 patients, the team applied lessons learned from historical studies and analyzed
how successful sites were recruiting their patients as compared to the lower-enrolling sites. They noted
that some sites’ recruitment protocols were more geared toward non-ICU studies. As there was no “one
size fits all” formula, the team applied a multi-faceted approach to cover all regions and countries to best
position the study for success.
Covance CRAs partnered with these sites, providing assistance through motivational visits and
discussions with ICU staff. Key success messages were then shared amongst the entire team.
As sites improved their recruitment rates, investigators were sent personal, handwritten thank
you notes to recognize their contribution to the research. Covance also incorporated their success
stories into the investigator meetings, inviting higher enrolling PIs from the region to share their
lessons learned so that other sites could gain insights on how to improve their results.
As the enrollment rapidly progressed, the Covance team tackled a backlog of data entry to support
DMC cuts as well as achieve an on-time database lock. Covance CRAs proactively partnered with
their sites to establish plans to efficiently enter data prior to the next monitoring visit so Source
Data Verification (SDV) could be completed. In turn, the project management team reviewed
metrics on a weekly basis and communicated their findings to the CRAs.
The Results: Meeting and beating expectations by 3 weeks
With the coordinated efforts to boost recruitment, the team reached the goal of recruiting 725 patients
three weeks ahead of deadline and met all site requirements, despite the difficult environment. They also
managed the influx of patient data and worked together to reach database lock and deliver the clinical
study report on time. From the start up group to the ethics committee, the Covance teams formed
cross-functional partnerships to increase communication, identify potential areas of risk and develop
mitigation strategies to prevent issues from occurring or solve challenges in real time.
The Lessons Learned: Leveraging established relationships and
experience
From this study, Covance has fostered its strong relationships with experienced investigators as well
as a robust list of sites that have proven success in enrolling ventilated patients in these complex
studies. Along with an understanding of antibiotic resistance rates and an experienced, global,
medical monitoring team that can quickly address issues, Covance knows how to ensure a sponsor
is fully supported from study start up to the submission of the final clinical study report.
Learn more about our drug development solutions at www.covance.com
Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory
Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the
marketing name for Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623)  +1.609.452.4440
Europe / Africa  +00.800.2682.2682 +44.1423.500888
Asia Pacific  +800.6568.3000 +65.6.5686588
© Copyright 2018 Covance Inc. CSCDS114-0518

More Related Content

What's hot

Training medical policy program final version 3
Training medical policy program final version 3Training medical policy program final version 3
Training medical policy program final version 3
Emily Barton
 

What's hot (20)

Implementing and Evaluating the Hospital Guide to Reducing Medicaid Readmissions
Implementing and Evaluating the Hospital Guide to Reducing Medicaid ReadmissionsImplementing and Evaluating the Hospital Guide to Reducing Medicaid Readmissions
Implementing and Evaluating the Hospital Guide to Reducing Medicaid Readmissions
 
OCT 2016 KJA Slides _FINAL
OCT 2016 KJA Slides _FINALOCT 2016 KJA Slides _FINAL
OCT 2016 KJA Slides _FINAL
 
Engage, Retain and Collect Data Directly from Patients in Late Phase Studies
Engage, Retain and Collect Data Directly from Patients in Late Phase StudiesEngage, Retain and Collect Data Directly from Patients in Late Phase Studies
Engage, Retain and Collect Data Directly from Patients in Late Phase Studies
 
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
 
Christie 2015 Resume
Christie 2015 ResumeChristie 2015 Resume
Christie 2015 Resume
 
Meeting Milestones and Delivering Successful Outcomes for a Phase I Parkinson...
Meeting Milestones and Delivering Successful Outcomes for a Phase I Parkinson...Meeting Milestones and Delivering Successful Outcomes for a Phase I Parkinson...
Meeting Milestones and Delivering Successful Outcomes for a Phase I Parkinson...
 
Shared Care Plan Trials - Progress to Date
Shared Care Plan Trials - Progress to DateShared Care Plan Trials - Progress to Date
Shared Care Plan Trials - Progress to Date
 
Readiness to Train Assessment Tool™ - National Launch
Readiness to Train Assessment Tool™ - National LaunchReadiness to Train Assessment Tool™ - National Launch
Readiness to Train Assessment Tool™ - National Launch
 
Clinical trial recruitment overview
Clinical trial recruitment overviewClinical trial recruitment overview
Clinical trial recruitment overview
 
Bea Brown | a locally tailored intervention to improve adherence to a clinica...
Bea Brown | a locally tailored intervention to improve adherence to a clinica...Bea Brown | a locally tailored intervention to improve adherence to a clinica...
Bea Brown | a locally tailored intervention to improve adherence to a clinica...
 
IHE / RSNA Image Sharing Project - IHE Colombia Workshop (12/2014) Module 5c
IHE / RSNA Image Sharing Project - IHE Colombia Workshop (12/2014) Module 5cIHE / RSNA Image Sharing Project - IHE Colombia Workshop (12/2014) Module 5c
IHE / RSNA Image Sharing Project - IHE Colombia Workshop (12/2014) Module 5c
 
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventSafety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
 
Patient recruitment into clinical trials presentation
Patient recruitment into clinical trials presentationPatient recruitment into clinical trials presentation
Patient recruitment into clinical trials presentation
 
Initial Medical Policy and Model Coverage Guidelines
Initial Medical Policy and Model Coverage GuidelinesInitial Medical Policy and Model Coverage Guidelines
Initial Medical Policy and Model Coverage Guidelines
 
Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment LandscapeRheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape
 
Training medical policy program final version 3
Training medical policy program final version 3Training medical policy program final version 3
Training medical policy program final version 3
 
PCORnet: Building Evidence through Innovation and Collaboration
PCORnet: Building Evidence through Innovation and CollaborationPCORnet: Building Evidence through Innovation and Collaboration
PCORnet: Building Evidence through Innovation and Collaboration
 
Certified Nurse Leader (CNL) Capstone Project
Certified Nurse Leader (CNL) Capstone ProjectCertified Nurse Leader (CNL) Capstone Project
Certified Nurse Leader (CNL) Capstone Project
 
Same-Visit Contraception: Implementation Strategies from the Field
Same-Visit Contraception: Implementation Strategies from the FieldSame-Visit Contraception: Implementation Strategies from the Field
Same-Visit Contraception: Implementation Strategies from the Field
 
IMS Health Clinical Trial Optimization Solutions
IMS Health Clinical Trial Optimization SolutionsIMS Health Clinical Trial Optimization Solutions
IMS Health Clinical Trial Optimization Solutions
 

Similar to Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Case Study

Nursing Research and Evidence Based Practice DQ.pdf
Nursing Research and Evidence Based Practice DQ.pdfNursing Research and Evidence Based Practice DQ.pdf
Nursing Research and Evidence Based Practice DQ.pdf
bkbk37
 
Module 5 (week 9) - InterventionAs you continue to work on your .docx
Module 5 (week 9) - InterventionAs you continue to work on your .docxModule 5 (week 9) - InterventionAs you continue to work on your .docx
Module 5 (week 9) - InterventionAs you continue to work on your .docx
roushhsiu
 
Exodon - Company Profile and Service Overview
Exodon - Company Profile and Service OverviewExodon - Company Profile and Service Overview
Exodon - Company Profile and Service Overview
Paul Ernest de Leon
 
Clinical Data Management Agenda
Clinical Data Management AgendaClinical Data Management Agenda
Clinical Data Management Agenda
Tracey Zdravkovic
 

Similar to Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Case Study (20)

Using Data to Overcome Recruitment and Retention Issues for Stroke Patients
Using Data to Overcome Recruitment and Retention Issues for Stroke PatientsUsing Data to Overcome Recruitment and Retention Issues for Stroke Patients
Using Data to Overcome Recruitment and Retention Issues for Stroke Patients
 
Innovations in Phase I Patient Recruitment for Alzheimer's disease
Innovations in Phase I Patient Recruitment for Alzheimer's diseaseInnovations in Phase I Patient Recruitment for Alzheimer's disease
Innovations in Phase I Patient Recruitment for Alzheimer's disease
 
Expanding Patient Enrollment and Site Activation Study Case Study: Partnershi...
Expanding Patient Enrollment and Site Activation Study Case Study: Partnershi...Expanding Patient Enrollment and Site Activation Study Case Study: Partnershi...
Expanding Patient Enrollment and Site Activation Study Case Study: Partnershi...
 
Ensuring a Pediatric Patient's Safety During a Global Rare Disease Trial
Ensuring a Pediatric Patient's Safety During a Global Rare Disease Trial Ensuring a Pediatric Patient's Safety During a Global Rare Disease Trial
Ensuring a Pediatric Patient's Safety During a Global Rare Disease Trial
 
Successfully Piloting a Virtual Real-World Evidence Study Case Study
Successfully Piloting a Virtual Real-World Evidence Study Case StudySuccessfully Piloting a Virtual Real-World Evidence Study Case Study
Successfully Piloting a Virtual Real-World Evidence Study Case Study
 
Partnering with Stakeholders to Drive a Successful Phase I/II Spinal Cord Inj...
Partnering with Stakeholders to Drive a Successful Phase I/II Spinal Cord Inj...Partnering with Stakeholders to Drive a Successful Phase I/II Spinal Cord Inj...
Partnering with Stakeholders to Drive a Successful Phase I/II Spinal Cord Inj...
 
CROs Driving Changes in Patient Recruitment
CROs Driving Changes in Patient RecruitmentCROs Driving Changes in Patient Recruitment
CROs Driving Changes in Patient Recruitment
 
How to improve clinical trial recruitment
How to improve clinical trial recruitment How to improve clinical trial recruitment
How to improve clinical trial recruitment
 
Cystic Fibrosis Drug Development Solutions
Cystic Fibrosis Drug Development Solutions Cystic Fibrosis Drug Development Solutions
Cystic Fibrosis Drug Development Solutions
 
Virtual clinical trials
Virtual clinical trialsVirtual clinical trials
Virtual clinical trials
 
Nursing Research and Evidence Based Practice DQ.pdf
Nursing Research and Evidence Based Practice DQ.pdfNursing Research and Evidence Based Practice DQ.pdf
Nursing Research and Evidence Based Practice DQ.pdf
 
Module 5 (week 9) - InterventionAs you continue to work on your .docx
Module 5 (week 9) - InterventionAs you continue to work on your .docxModule 5 (week 9) - InterventionAs you continue to work on your .docx
Module 5 (week 9) - InterventionAs you continue to work on your .docx
 
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
 
Amarini_BMJ
Amarini_BMJAmarini_BMJ
Amarini_BMJ
 
Putting the Oncology Patient First
Putting the Oncology Patient FirstPutting the Oncology Patient First
Putting the Oncology Patient First
 
Exodon - Company Profile and Service Overview
Exodon - Company Profile and Service OverviewExodon - Company Profile and Service Overview
Exodon - Company Profile and Service Overview
 
A Smart Alternative For Specimen Collection - Patient Service Center Visits
A Smart Alternative For Specimen Collection - Patient Service Center Visits A Smart Alternative For Specimen Collection - Patient Service Center Visits
A Smart Alternative For Specimen Collection - Patient Service Center Visits
 
Real-Time Data. Real-World Impact. Info sheet
Real-Time Data. Real-World Impact. Info sheet Real-Time Data. Real-World Impact. Info sheet
Real-Time Data. Real-World Impact. Info sheet
 
PIIS1526411415004394
PIIS1526411415004394PIIS1526411415004394
PIIS1526411415004394
 
Clinical Data Management Agenda
Clinical Data Management AgendaClinical Data Management Agenda
Clinical Data Management Agenda
 

More from Covance

More from Covance (20)

Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
 
Genomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisGenomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome Analysis
 
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for Biosimilars
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development Solutions
 
Inhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsInhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory Treatments
 
Covance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance Laboratory FSPx Solutions
Covance Laboratory FSPx Solutions
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
 
Environmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsEnvironmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical Drugs
 
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramPutting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
 
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketTop 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
 
Covance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance Phase IV Solutions Brochure
Covance Phase IV Solutions Brochure
 
Optimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceOptimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access Experience
 
Patient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochurePatient Safety Cloud Solution Brochure
Patient Safety Cloud Solution Brochure
 
Plant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationPlant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant Cultivation
 
Biocide Authorization Timeline
Biocide Authorization TimelineBiocide Authorization Timeline
Biocide Authorization Timeline
 
K-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH LegislationK-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH Legislation
 

Recently uploaded

Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
AnaAcapella
 
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
EADTU
 

Recently uploaded (20)

Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
 
Play hard learn harder: The Serious Business of Play
Play hard learn harder:  The Serious Business of PlayPlay hard learn harder:  The Serious Business of Play
Play hard learn harder: The Serious Business of Play
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptx
 
Simple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfSimple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdf
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food Additives
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdfUGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
VAMOS CUIDAR DO NOSSO PLANETA! .
VAMOS CUIDAR DO NOSSO PLANETA!                    .VAMOS CUIDAR DO NOSSO PLANETA!                    .
VAMOS CUIDAR DO NOSSO PLANETA! .
 
OSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & SystemsOSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & Systems
 
Our Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdfOur Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdf
 

Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Case Study

  • 1. Hospital-Acquired Pneumonia/ Ventilator-Associated Pneumonia (HAP/VAP) Case Study IMPROVING STUDY START UP AND RECRUITMENT FOR A DRUG-DEVICE CLINICAL TRIAL Ventilated patients in a hospital setting are at risk of developing pneumonia, which is often treated with an IV-delivered antibiotic. In collaboration with an agile biotech company, a large pharmaceutical company was running a program to investigate the clinical efficacy and safety of a drug-device combination for intubated, mechanically ventilated patients by delivering a localized, lower dosage of an antibiotic within the lungs as compared to systemically-administered antibiotics. Due to the sponsor’s shifting alliance agreements, Covance was selected to assume its in-progress, Phase III clinical trial. This case study explores the challenges faced in study start up, recruitment and data management. The Challenges: Recruiting a global population in a complex infectious disease study ICU studies are inherently difficult due to the complexities of patients’ conditions while in the hospital, the need to obtain consent for temporarily incapacitated patients and the massive amount of associated data that is generated in the medical records. When Covance received this study, there had already been three amendments to the protocol and the trial was behind schedule for startup and recruitment. With over 250 sites encompassing 25 different countries and their respective regulatory requirements involved, Covance needed to quickly make major progress to get the study back on track. Initial enrollment criteria were very strict, allowing only a 24-hour window to complete patient screening and start the study regimen. While standard of care assessments were allowed, it was still challenging to enroll patients. The final challenge involved managing the data cleaning process with the sponsor to support the Data Monitoring Committee (DMC), as many data points were collected and had to be correctly mapped within the Electronic Data Capture (EDC) system. Key Actions ▶ Developed hands-on solutions to address lagging recruitment ▶ Worked directly with sites to understand the barriers to recruitment and share success stories among investigators ▶ Built a robust communications effort to meet the recruitment goals, achieve database lock and submit the clinical study report (CSR) on time
  • 2. The Actions: Setting up sites for success Covance first worked with the sponsor to amend the protocol and allow for a 48-hour window instead of the initial restrictive 24-hour window to increase the potential for successful enrollment. With the goal of recruiting 725 patients, the team applied lessons learned from historical studies and analyzed how successful sites were recruiting their patients as compared to the lower-enrolling sites. They noted that some sites’ recruitment protocols were more geared toward non-ICU studies. As there was no “one size fits all” formula, the team applied a multi-faceted approach to cover all regions and countries to best position the study for success. Covance CRAs partnered with these sites, providing assistance through motivational visits and discussions with ICU staff. Key success messages were then shared amongst the entire team. As sites improved their recruitment rates, investigators were sent personal, handwritten thank you notes to recognize their contribution to the research. Covance also incorporated their success stories into the investigator meetings, inviting higher enrolling PIs from the region to share their lessons learned so that other sites could gain insights on how to improve their results. As the enrollment rapidly progressed, the Covance team tackled a backlog of data entry to support DMC cuts as well as achieve an on-time database lock. Covance CRAs proactively partnered with their sites to establish plans to efficiently enter data prior to the next monitoring visit so Source Data Verification (SDV) could be completed. In turn, the project management team reviewed metrics on a weekly basis and communicated their findings to the CRAs. The Results: Meeting and beating expectations by 3 weeks With the coordinated efforts to boost recruitment, the team reached the goal of recruiting 725 patients three weeks ahead of deadline and met all site requirements, despite the difficult environment. They also managed the influx of patient data and worked together to reach database lock and deliver the clinical study report on time. From the start up group to the ethics committee, the Covance teams formed cross-functional partnerships to increase communication, identify potential areas of risk and develop mitigation strategies to prevent issues from occurring or solve challenges in real time. The Lessons Learned: Leveraging established relationships and experience From this study, Covance has fostered its strong relationships with experienced investigators as well as a robust list of sites that have proven success in enrolling ventilated patients in these complex studies. Along with an understanding of antibiotic resistance rates and an experienced, global, medical monitoring team that can quickly address issues, Covance knows how to ensure a sponsor is fully supported from study start up to the submission of the final clinical study report. Learn more about our drug development solutions at www.covance.com Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623)  +1.609.452.4440 Europe / Africa  +00.800.2682.2682 +44.1423.500888 Asia Pacific  +800.6568.3000 +65.6.5686588 © Copyright 2018 Covance Inc. CSCDS114-0518